|
Video: What is a Stock Split?
|
|
Alnylam Pharmaceuticals is a global biopharmaceutical company developing therapeutics based on ribonucleic acid interference (RNAi). Co. has four RNAi-based medicines, ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran) and Leqvio® (inclisiran). ONPATTRO is approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. GIVLAARI is approved for the treatment of adults with acute hepatic porphyria. Co. has approval for OXLUMO for the treatment of primary hyperoxaluria type 1 in all age groups. Leqvio (inclisiran) is being developed and commercialized for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. According to our Alnylam Pharmaceuticals stock split history records, Alnylam Pharmaceuticals has had 0 splits. | |
|
Alnylam Pharmaceuticals (ALNY) has 0 splits in our Alnylam Pharmaceuticals stock split history database.
Looking at the Alnylam Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Alnylam Pharmaceuticals shares, starting with a $10,000 purchase of ALNY, presented on a split-history-adjusted basis factoring in the complete Alnylam Pharmaceuticals stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/29/2014 |
|
End date: |
04/25/2024 |
|
Start price/share: |
$50.95 |
|
End price/share: |
$143.71 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
182.06% |
|
Average Annual Total Return: |
10.93% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$28,207.64 |
|
Years: |
10.00 |
|
|
|
|
|